WHO ICTRP trial
A Phase 2b, Open-Label Study of Selinexor (KPT-330) in Patients with…
NL-OMON46935 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON46935 |
|---|---|
| Public title | A Phase 2b , Open-Label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| Scientific title | A Phase 2b , Open-Label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - SADAL: Selinexor Against Diffuse Aggressive Lymphoma |
| Primary sponsor | Karyopharm Therapeutics, Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Lymphoma relapse/refractory Diffuse large B-cell lyphoma;10025323;Lymphoma;relapse/refractory Diffuse large B-cell lyphoma |
| Interventions | Selinexor will be given at an oral fixed milligram (mg) dose of 60 mg on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1 to 4 of each 4 week cycle (total of 8 doses per cycle). Patients who achieve a… |
| Registration date | Oct 16, 2018 |
| Target size | 10 |
| Secondary IDs | 2014-001977-15;NCT02227251;NL56132.029.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: